Clinical Evaluation of the Results of Treatment of Severe Coronavirus Disease (COVID-19) Caused by SARS-COV-2 in Patients with Pneumonia and Pneumo-Pleurofibrosis Using Modern Pharmacotherapy to Protect Public Health
SSP Modern Pharmacy and Medicine · 28.01.2026 · 6 (1) · 16
DOI: 10.53933/qdzmtx24 ↗Kurz gefasst
Fachartikel in der Zeitschrift SSP Modern Pharmacy and Medicine, online erschienen am 28.01.2026. Verfasst von Oleksandr Nevzghoda und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The COVID-19 pandemic prompted the development of innovative approaches to the treatment of severe forms of pneumonia with pneumo-pleurofibrosis. An IV regimen based on intravenous administration of ethyl alcohol solutions of different concentrations with glucose in patients with COVID-19 (intervention group and control groups of comparable number) was proposed and clinically evaluated. The use of 10% Ethanol has been introduced: 150 ml intravenously drip 2 times a day for 7 days. In both groups, hyperthermia, tachypnea, dry cough, pleural pain, diffuse cyanosis, severe general condition, a significant decrease in oxygen saturation, leukocytosis and lymphopenia were found at the beginning of treatment. In the intervention group, the normalization of indicators occurred much faster: body temperature returned to normal on the fifth to seventh day versus the twelfth-fourteenth in the control; respiratory rate – on the fourth to fifth day versus the sixteenth to eighteenth; saturation reached normal on the sixth to eighth day against the twelfth-fifteenth; leukocytes returned to normal on the tenth to eleventh day against the sixteenth to eighteenth; Lymphocytes stabilized on the sixth to eighth day versus the twentieth to twenty-second. On the seventh day, a satisfactory condition was observed in most patients in the intervention group without deaths, in the control - much later and in smaller numbers. The technique of using intravenous ethanol is based on the classical principles of detoxification therapy: elimination of the toxic factor with subsequent elimination of the consequences of intoxication, which provides an etiotropic-pathogenetic effect in acute vasculitis and pneumo-pleurofibrosis. The proposed scheme reduces the duration of treatment, reduces costs, and requires further clinical, pharmacological and pharmacoeconomic studies.
Zitieren
APA
Nevzghoda, O., Nevzghoda, A., & Chuiev, Y. (2026). Clinical Evaluation of the Results of Treatment of Severe Coronavirus Disease (COVID-19) Caused by SARS-COV-2 in Patients with Pneumonia and Pneumo-Pleurofibrosis Using Modern Pharmacotherapy to Protect Public Health. SSP Modern Pharmacy and Medicine, 6(1), 16. https://doi.org/10.53933/qdzmtx24
Vancouver
Nevzghoda O, Nevzghoda A, Chuiev Y. Clinical Evaluation of the Results of Treatment of Severe Coronavirus Disease (COVID-19) Caused by SARS-COV-2 in Patients with Pneumonia and Pneumo-Pleurofibrosis Using Modern Pharmacotherapy to Protect Public Health. SSP Modern Pharmacy and Medicine. 2026;6(1):16. doi:10.53933/qdzmtx24
BibTeX
@article{Nevzghoda2026,
author = {Nevzghoda, Oleksandr and Nevzghoda, Anatoly and Chuiev, Yuriy},
title = {Clinical Evaluation of the Results of Treatment of Severe Coronavirus Disease (COVID-19) Caused by SARS-COV-2 in Patients with Pneumonia and Pneumo-Pleurofibrosis Using Modern Pharmacotherapy to Protect Public Health},
journal = {SSP Modern Pharmacy and Medicine},
year = {2026},
volume = {6},
number = {1},
pages = {16},
doi = {10.53933/qdzmtx24}
}
EUVIMED